AVTX
HEALTHCAREAvalo Therapeutics Inc
What's Moving AVTX Today?
No stock-specific AI insight has been generated for AVTX yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring AVTX
52-Week Range
$17.83
Fundamentals
Trading
AVTX News
23 articles- Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026Yahoo Finance·Jun 23, 2026
- Avalo Therapeutics Appoints Ron Philip to Board of DirectorsYahoo Finance·Jun 23, 2026
- Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β AntibodyYahoo Finance·Jun 16, 2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo Finance·Jun 12, 2026
- Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 22, 2026
- Avoro holds 1.41M shares in Avalo Therapeutics (NASDAQ: AVTX)Stock Titan·May 15, 2026
- Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Losswww.marketscreener.com·May 13, 2026
- Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q SummaryTradingView·May 13, 2026
- Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesYahoo Finance·May 13, 2026
- This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A BreakoutYahoo Finance·May 6, 2026
- Avalo shares spike on skin drug data; BioNTech to cut staffBiopharmadive·May 6, 2026
- Avalo Therapeutics Announces Pricing of $375 Million Public OfferingGlobeNewswire Inc.·May 6, 2026
- Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·May 5, 2026
- Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis SuppurativaYahoo Finance·May 5, 2026
- Avalo Therapeutics Purchases Optional Milestone BuyoutYahoo Finance·Apr 28, 2026
- Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo TherapeuticsYahoo Finance·Apr 6, 2026
- Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth PlansYahoo Finance·Apr 6, 2026
- Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More247 Wall St·Apr 6, 2026
- Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should KnowYahoo Finance·Apr 3, 2026
- 5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthYahoo Finance·Apr 2, 2026
- CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian CancerYahoo Finance·Mar 26, 2026
- Avalo Therapeutics Reports 2025 Financial Results and Recent Business UpdatesYahoo Finance·Mar 23, 2026
- Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at ConferenceMarketbeat·Mar 12, 2026
All 23 articles loaded
Price Data
52-Week Range
$17.83
Fundamentals
Trading
About Avalo Therapeutics Inc
Avalo Therapeutics Inc is a clinical-stage biotechnology company dedicated to innovating therapies for rare and underserved diseases, particularly in the realm of immunological regulation. The company boasts a strong pipeline of proprietary drug candidates that target serious conditions characterized by significant unmet medical needs, underscoring its commitment to advancing healthcare solutions. Leveraging its extensive expertise in disease mechanisms and thorough clinical trial methodologies, Avalo is strategically positioned to develop transformative therapies. By maintaining a strong focus on patient-centric approaches, Avalo aims to enhance therapeutic outcomes and create meaningful changes in patients' lives, reflecting its potential to make a profound impact in the biopharmaceutical sector.